MARKET

MDGL

MDGL

Madrigal Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

118.19
+0.29
+0.25%
Closed 16:00 09/25 EDT
OPEN
118.52
PREV CLOSE
117.90
HIGH
121.50
LOW
117.65
VOLUME
75.21K
TURNOVER
--
52 WEEK HIGH
127.25
52 WEEK LOW
56.82
MARKET CAP
1.82B
P/E (TTM)
-13.5751
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Madrigal Pharma exceeds target enrollment in late-stage MAESTRO NAFLD-1 trial
Madrigal Pharmaceuticals (MDGL) announces that it has already exceeded the originally targeted enrollment of 700 patients in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with NASH and fibrosis
Seekingalpha · 09/03 12:35
Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial
\--Completion of enrollment in MAESTRO-NAFLD-1 will enable reporting of topline 52-week data by the end of next year as planned. \--Madrigal intends to present selected data from ongoing open label arm by the end of 2020 \--Recent presentations at EASL Digital ILC of secondary analysis
GlobeNewswire · 09/03 10:50
Intercept Pharmaceuticals Will Lay Off a Quarter of Its Staff as NASH Dream Fades
The company was once the front-runner in the race to develop a treatment for NASH, a newly defined liver disease
Barrons.com · 09/02 15:20
Madrigal Pharmaceuticals stock price target raised to $143 from $127 at UBS
MDGL | Complete Madrigal Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
marketwatch.com · 09/02 12:58
Viking Therapeutics' VK2809 shows durable effect in mid-stage fatty liver study
Viking Therapeutics (VKTX) announces new data from a 12-week Phase 2 clinical trial evaluating VK2809 in patients with nonalcoholic fatty liver disease ((NAFLD)) and elevated low-density lipoprotein cholesterol (LDL-C) ("bad"
Seekingalpha · 08/28 10:57
Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress 2020
CONSHOHOCKEN, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that on Friday, August 28, 2020 at the Digital International Liver Congress™ 2020, European Association for the Study of the Liver (EASL), secondary analyses of data from its Phase 2 NASH
GlobeNewswire · 08/26 11:50
NGM Bio a stock to watch ahead of key NASH presentation
NGM Biopharmaceuticals (NGM) announces that comprehensive data from its 24-week Phase 2 clinical trial evaluating aldafermin in patients with nonalcoholic steatohepatitis ((NASH)) will be featured in an oral plenary session
Seekingalpha · 08/18 12:47
Madrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights
CONSHOHOCKEN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and highlights: “The Madrigal team and our CRO’s are focused on completing enrollment of both of our Ph
GlobeNewswire · 08/06 10:50
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MDGL. Analyze the recent business situations of Madrigal Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MDGL stock price target is 172.93 with a high estimate of 250.00 and a low estimate of 114.00.
EPS
Institutional Holdings
Institutions: 189
Institutional Holdings: 11.77M
% Owned: 76.24%
Shares Outstanding: 15.44M
TypeInstitutionsShares
Increased
46
696.80K
New
38
127.58K
Decreased
35
657.13K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Chief Executive Officer/Director
Paul Friedman
Chief Financial Officer/Senior Vice President
Marc Schneebaum
Corporate Executive/Director
Rebecca Taub
Senior Vice President/General Counsel
Brian Lynch
Senior Vice President
Remy Sukhija
Lead Director/Independent Director
Frederick Craves
Independent Director
Kenneth Bate
Independent Director
James Daly
Independent Director
Keith Gollust
Independent Director
Richard Levy
Independent Director
David Milligan
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MDGL
Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Madrigal Pharmaceuticals Inc stock information, including NASDAQ:MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.